<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="6.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bentz, Bradford G</style></author><author><style face="normal" font="default" size="100%">Maxwell, Lara K</style></author><author><style face="normal" font="default" size="100%">Erkert, Ronald S</style></author><author><style face="normal" font="default" size="100%">Royer, Christopher M</style></author><author><style face="normal" font="default" size="100%">Davis, Michael S</style></author><author><style face="normal" font="default" size="100%">MacAllister, Charles G</style></author><author><style face="normal" font="default" size="100%">Clarke, Cyril R</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Pharmacokinetics of acyclovir after single intravenous and oral administration to adult horses.</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of veterinary internal medicine / American College of Veterinary Internal Medicine</style></secondary-title><alt-title><style face="normal" font="default" size="100%">J. Vet. Intern. Med.</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Acyclovir</style></keyword><keyword><style  face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">Antiviral Agents</style></keyword><keyword><style  face="normal" font="default" size="100%">Area Under Curve</style></keyword><keyword><style  face="normal" font="default" size="100%">Chromatography, High Pressure Liquid</style></keyword><keyword><style  face="normal" font="default" size="100%">Cross-Over Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Herpesviridae Infections</style></keyword><keyword><style  face="normal" font="default" size="100%">Herpesvirus 1, Equid</style></keyword><keyword><style  face="normal" font="default" size="100%">Horse Diseases</style></keyword><keyword><style  face="normal" font="default" size="100%">Horses</style></keyword><keyword><style  face="normal" font="default" size="100%">Injections, Intravenous</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2006</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2006 May-Jun</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">20</style></volume><pages><style face="normal" font="default" size="100%">589-94</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">The purpose of the study reported here was to describe the bioavailability and pharmacokinetics of acyclovir after intravenous and oral administration to horses. Six healthy adult horses were used in a randomized cross-over study with a 3 x 3 Latin square design. Three treatments were administered to each horse: 10 mg of injectable acyclovir/kg of body weight in 1 L of normal saline delivered as an infusion over 15 minutes; 10 mg of acyclovir/kg in tablets by nasogastric intubation; and 20 mg of acyclovir/kg in tablets by nasogastric intubation. A 2-week washout period was provided between each treatment. Serum samples were obtained for acyclovir assay using reversed-phase, high-performance liquid chromatography with fluorescence detection. Deproteinated serum was injected onto a C18 column, and elution occurred under isocratic conditions. The limit of quantification was 0.04 microg/mL. The assay exhibited suitable accuracy, precision, and recovery. The IV data were analyzed by a 3-compartment model, and oral data were analyzed noncompartmentally. Intragastric acyclovir administration at either dose was associated with high variability in serum acyclovir-time profiles, low Cmax, and poor bioavailability. The dosage of 20 mg/kg was associated with mean (+/- SD) Cmax of 0.19 +/- 0.10 microg/mL, and bioavailability was 2.8%. Inhibition of equine herpesvirus has been reported to require significantly higher acyclovir concentrations than those obtained here. The results of this study do not support a therapeutic benefit for the oral administration of acyclovir up to doses of 20 mg/kg.</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><custom1><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/pubmed/16734094?dopt=Abstract</style></custom1></record></records></xml>